A Phase 2 interventional study of Stereotactic Body Radiation Therapy (SBRT) and Systemic therapy in Castrate Resistance Prostate Cancer and OligoProgressive Metastatic Disease, sponsored by University Health Network, Toronto. Recruiting at 1 site in Canada. Open to male participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-07-07.
Sponsored by University Health Network, Toronto · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 102 studies in Prostatic Neoplasms by University Health Network, Toronto — 23 open to participants now, 29 under way, 2 of them phase 3. Prostatic Neoplasms · University Health Network, Toronto.
Among the 102 studies in Prostatic Neoplasms by University Health Network, Toronto, this one is the 30th largest by planned enrollment of the 86 interventional ones that give a count, is one of 5 that started in 2025, is one of 29 in phase 2, reaches primary completion later than 23 of the 28 other live ones, and was the 96th registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →23 of the 102 studies in Prostatic Neoplasms by University Health Network, Toronto are open now, in 1 country. Recruiting first, the newest first:
University Health Network, Toronto · Sites in Canada
Ages 18+ · Men only
University Health Network, Toronto · Sites in Canada
Ages 18+ · Men only
University Health Network, Toronto · Sites in Canada
Ages 18+ · Men only
University Health Network, Toronto · Sites in Canada
Ages 40–85 · Men only
University Health Network, Toronto · Sites in Canada
Ages 18+ · Men only
By country, each count listing its studies:
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years to 100 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
102 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 35 · Phase 3 4 · Phase 4 2
First in 1999; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 75 is above the median of 60 across 5,358 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 44 across the 86 interventional studies, 82 across the 13 observational. Of the 67 that completed or were terminated, 1 (1%) have results posted.
This tab as a report to print or save as PDF → With an account.
University Health Network, Toronto is the lead sponsor of 1,441 studies on the registry; 298 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 3 (18%) have results posted.
8 of the studies in Prostatic Neoplasms by University Health Network, Toronto that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06877598University Health Network, TorontoCanada-wide Implementation of a Virtual Sexual Health and Rehabilitation eClinic (SHAReClinic) for Prostate Cancer Patients and Their Partners | 2026-12 |
| NCT05033301University Health Network, TorontoEvaluating the Effectiveness of the Nurse Ned Clinic | 2026-12-30 |
| NCT05582772University Health Network, TorontoTOward a comPrehensive Supportive Care Intervention for Older Men With Metastatic Prostate Cancer | 2027-02-28 |
| NCT00913939University Health Network, TorontoHigh-Dose-Rate Brachytherapy | 2027-05 |
| NCT07747493University Health Network, Toronto68Ga-PSMA-11 PET/MRI for Selecting Men With Prostate Cancer for Focal Therapy | 2027-07-31 |
Add all 8 to your calendar (.ics) → With an account.
Among the 102 studies in Prostatic Neoplasms by University Health Network, Toronto, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a single centre, interventional, randomized Phase II, two-arm prospective trial investigating if Stereotactic Body Radiotherapy (SBRT) to all sites of Oligopressive (OP) disease while remaining on current Systemic Therapy (ST) will improve biochemical control compared to Standard of Care (SoC) (which involves a change in ST) for patients with OP Castrate Resistance Prostate Cancer (CRPC).
The current standard of care for patients with metastatic Oligopressive (OP) Castrate Resistance Prostate Cancer (CRPC) is a change in Systemic Therapy (ST). We propose that Stereotactic Body Radiotherapy (SBRT) to Oligopressive sites, while maintaining patients on their current Systemic Therapy, may allow for biochemical control of disease while maintaining patient Quality of Life and avoiding the toxicities associated with changing Systemic Therapy. We have proposed an initial prospective feasibility study, followed by a larger phase II prospective study to investigate the efficacy of SBRT in Oligopressive Castrate Resistance Prostate Cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants on Arm 1 - SOC will be treated as per standard of care by their treating Oncologist. In most instances, it is anticipated participants will undergo a change in Systemic Therapy (ST) (including best supportive care). The ST will be at the discretion of the Oncologist and patient, according to best practices for the patient's diagnosis and clinical scenario. Patients can receive palliative radiotherapy for standard indications at any time.
Radiation: Stereotactic Body Radiation Therapy (SBRT) · Other: Systemic therapy
Participants on Arm 2 - Experimental will receive standard of care SBRT to oligoprogressive sites according to institutional standards while remaining on the systemic treatment prescribed by the treating oncologist.
Radiation: Stereotactic Body Radiation Therapy (SBRT) · Other: Systemic therapy
SBRT will be delivered as per institutional standard.
Participants will receive Systemic Therapy. Participants in Arm 1 - SOC may change the Systemic Therapy throughout treatment. Participants in Arm 2 - Experimental will remain on the same Systemic Therapy throughout treatment.
Study Feasibility
Determine the feasibility of enrolling 21 patients patients onto a study randomizing patients to either MDT using SBRT plus remaining on current ST versus SoC (change in Systemic Therapy) by measuring the rate accrual (number of patients per month for 18 months).
Time frame: Within 18 months of study activation.
Change in Prostate-Specific Antigen (PSA)
Assess by standard PSA blood testing if the proportion of patients having a \>50% change in PSA compared to baseline (PSA50) is improved with MDT using SBRT plus remaining on current ST versus SoC.
Time frame: Enrollment to 12 months post-enrollment.
Radiographic Local Control of Oligopressive Lesions
Radiographic local control of the index OP lesions will be assessed by treating oncologist.
Time frame: Enrollment to 12 months-post enrollment.
Radiographic Distant Control of Oligopressive Lesions
Defined by growth of non-Oligoprogressive metastatic sites and/or the development of new sites of metastatic disease, as assessed by treating oncologist.
Time frame: Enrollment to 12-months post-enrollment.
Progression Free Survival (PFS)
Defined as the time from randomization to death from any cause, progression of disease, or date of last follow-up, whichever occurs first. PFS will be assessed by the treating oncologist.
Time frame: Enrollment to 12-months post-enrollment.
Time to next Systemic Therapy
Defined as the time from when the study intervention has been commenced until commencement of any next systemic anti-cancer therapy (including a change to best supportive care) or date of last follow up, whichever occurs first, which will be assess by the treating oncologist.
Time frame: Enrollment to 12-months post-enrollment.
Differences in Toxicity
Toxicity will be assessed to determine whether SBRT compared to SoC results in patient- and/or physician-reported toxicity differences. Toxicity will be collected using CTCAE v5.0
Time frame: Enrollment to 12-months post-enrollment.
Differences in Quality of Life
Quality of Life (QoL) will be assessed to determine whether SBRT compared to SoC results in patient- and/or physician-reported QoL differences. QoL will be collected using the EORTC QLQ-C30 questionnaire.
Time frame: Enrollment to 12-months post-enrollment.
Started Jul 2025 (actual). Primary completion is estimated for Jun 2030, 59 months after the start.
Of 613 non-industry phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 86. This study's planned 59 months is close to that.
Counting every sponsor, half of 727 studies reached it within 53 months; a quarter within 34 and three quarters within 80.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Health Network, Toronto →